Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.
about
Current status of HIV infection: a review for non-HIV-treating physiciansNonnucleoside inhibitor of measles virus RNA-dependent RNA polymerase complex activityImpact of HIV/AIDS on care and outcomes of severe sepsis.Gender difference in advanced HIV disease and late presentation according to European consensus definitionsManagement of hepatitis C virus infection in HIV/HCV co-infected patients: Clinical reviewEfavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsLate HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US States, 1996-20048-Modified-2'-deoxyadenosine analogues induce delayed polymerization arrest during HIV-1 reverse transcriptionFrailty, HIV infection, and mortality in an aging cohort of injection drug usersFirst line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter studyExploring disparities between global HIV/AIDS funding and recent tsunami relief efforts: an ethical analysis.The Effect of a Community-Based Exercise Program on Inflammation, Metabolic Risk, and Fitness Levels Among Persons Living with HIV/AIDS.Efavirenz-associated QT prolongation and Torsade de Pointes arrhythmia.High-throughput screening-based identification of paramyxovirus inhibitors25 years of HIV-1 research - progress and perspectives.Comparison of emergency department HIV testing data with visit or patient as the unit of analysisCourse of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: five-year outcomes.Body Composition and Metabolic Syndrome Components on Lipodystrophy Different Subtypes Associated with HIVFuture prospects of health management systems using cellular phones.Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea in a human immunodeficiency virus-infected patient following highly active antiretroviral therapy.Magnitude and determinants of nonadherence and nonreadiness to highly active antiretroviral therapy among people living with HIV/AIDS in Northwest Ethiopia: a cross-sectional study.Personal and contextual factors related to delayed HIV diagnosis among men who have sex with men.Gender disparities in HIV health care utilization among the severely disadvantaged: can we determine the reasons?Kidney transplantation and HIV: does recipient privacy outweigh the donor's right to information?Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive statusHIV testing trends: Southeastern Pennsylvania, 2002-2010.The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention.Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infectionDrug use and medication adherence among HIV-1 infected individuals.Potential impact of antiretroviral therapy and screening on cervical cancer mortality in HIV-positive women in sub-Saharan Africa: a simulation.Addressing unmet need for HIV testing in emergency care settings: a role for computer-facilitated rapid HIV testing?Intervention to influence behaviors linked to risk of chronic diseases: a multisite randomized controlled trial with African-American HIV-serodiscordant heterosexual couples.HIV Reprograms Human Airway Basal Stem/Progenitor Cells to Acquire a Tissue-Destructive Phenotype.Analytical and biological considerations in the measurement of cell-associated CCR5 and CXCR4 mRNA and proteinNon-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.The efficacy of a computerized assessment of medication adherence in active substance users.Incidence and risk factors for AIDS-related mortality in HIV patients in China: a cross-sectional study.Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir.A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes
P2860
Q22242613-AA20FD37-7145-46AB-8CFC-BB184F195895Q24678611-97DCD57E-0AA9-43CA-BEA8-9721202A8CCAQ25255282-1109171B-ABBA-4257-96AB-B69292BC4DB5Q26786152-D1232AEB-3783-462D-8C1B-2374D79EB084Q27489337-511916B4-D529-480A-A1FE-CFE4D9073D14Q28081266-2A764346-4ED1-4C1E-A8ED-B22ECCFF51E1Q28474749-07FB3623-729E-4BBD-AD69-446F8A6210E3Q28477840-DD0C0558-741B-4655-B35A-3BE093FAC6E7Q28485898-E72CAEDD-5710-4935-9CAD-26AB1EDD3ACDQ28538326-BB09FC0D-6A06-429F-BEE9-54EC97DBCF81Q30360407-8FBE2C8E-C03A-421A-9170-396777B6EDAAQ30381883-3551CF96-C9CF-4C7D-B0D9-70F657044984Q33147714-CB75DE8D-828E-4CF0-9D00-C017E0962170Q33351623-1FB1195F-BA70-4966-B6D9-9C5C51536F05Q33381841-188BA30A-2ADE-43A1-B924-24A79F4DD86DQ33427350-BCBE18B5-EC56-4F20-A6B5-76B766772F23Q33646043-5454C3F1-0DB5-4E5B-B05D-4684B4A46BFBQ33678847-72CF7E84-44D4-474B-971F-6D098EAFEC59Q33687776-8CF9F03D-AAC7-40D0-AA67-23EC8560A930Q33722450-25147EF1-11A4-4B70-9B2F-32D30016A26AQ33753410-06637888-583C-42C8-8F8C-32DD81B1EE39Q33761399-40C619F8-301B-4E83-9CED-F4D59DE9350BQ33810823-D7050FAC-A047-4518-AAEC-5E0D82167336Q33827443-ACD1FEFC-0AA7-4E27-B76B-14F190BDFA7FQ33827543-329A5425-273A-4811-B49C-FABEC09A3D92Q33828318-74104915-E1CB-424F-AAAF-304C9EFAB271Q33828458-5279AADF-AE84-4A95-BCA4-BD026EBC8AADQ33834640-B60DD2CE-E7CA-4A71-8CF1-8DCD3A010503Q33841530-B5401213-FB15-4983-9492-CA4364548130Q33869309-B6D9DC0F-20B4-4898-A94F-374A804B36C2Q33878099-B9FAA0BD-5C53-4A6C-853E-D9BD4F37998EQ33881756-FE8C7B24-D4A8-4FD0-B6DF-8BD8D0DDD188Q33923363-FBAA69E0-F9A2-4737-8D31-3350EBC3A693Q33962644-359601D3-9B6A-4D92-81B5-A94F06C77020Q34037355-E35E1669-CF22-4FC9-AC52-913B106B5F64Q34045363-C7F60097-25E8-448E-8E68-52E3FF8609E1Q34049901-7E1B0AC7-40BB-4BB8-A93F-F29DCBBBE689Q34062712-465D5267-2194-4264-B945-DF21C924F1C3Q34100187-901EDA3E-72A1-465A-A347-AE3893144624Q34102058-0FC20A83-8723-467C-A543-22A25A125568
P2860
Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Highly active antiretroviral t ...... nts with advanced HIV disease.
@en
type
label
Highly active antiretroviral t ...... nts with advanced HIV disease.
@en
prefLabel
Highly active antiretroviral t ...... nts with advanced HIV disease.
@en
P2093
P1476
Highly active antiretroviral t ...... nts with advanced HIV disease.
@en
P2093
A C Collier
E L Murphy
F R Wallach
L A Kalish
S F Assmann
T P Flanigan
P356
10.7326/0003-4819-135-1-200107030-00005
P407
P577
2001-07-01T00:00:00Z